



Friday, October 16, 2020 13:00 – 18:20 CDT
Saturday, October 17, 2020 07:00 – 12:40 CDT

Everett Vokes & Heather Wakelee, NACLC 2020 Steering Committee Chairs
Jessica Donington & Julie Brahmer, NACLC 2020 Program Committee Co-Chairs

October 16, 2020

CHAIRS WELCOME

Session Chairs: Heather Wakelee & Ken Rosenzweig

Start	End	Event	Presenter
13:00	13:06	Chair's Welcome	Jessica Donington Julie Brahmer
13:06	13:16	Lung Ambition Alliance Update	Chandra Belani
13:16	13:18	Patient Perspective: COVID Survivor	Bob Steele
13:18	13:48	Real World Practical Application (Effects of COVID-19 on Lung Cancer Care and Implications)	Marina Garassino
13:48	14:00	Live Q&A	

IMMUNOTHERAPY

Session Chair: Ticiana Leal

Start	End	Event	Presenter
14:00	14:02	Patient Perspective: Immunotherapy	John Ryan
14:02	14:12	iO Therapy for Stage IV Therapies	Nasser Hanna
14:12	14:22	PACIFIC Nuances and What's Next?	Jhanelle Gray
14:22	14:32	Combining IO with Radiation Therapy	Steve Chmura
14:32	14:42	Moving iO into Early Stage Disease	Linda Martin
14:42	14:52	In Search of the Perfect Biomarker for IO	Lynette Sholl
14:52	15:05	Live Q&A	Ticiana Leal

15:05	15:20	BREAK	
-------	-------	--------------	--

ORAL ABSTRACT SESSION 1

Session Chair: Everett Vokes

Start	End	Event	Presenter
15:20	15:22	Patient Perspective	John Doll
15:22	15:30	Nivolumab (NIVO) + Ipilimumab (IPI) + 2 Cycles of Platinum-doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-line (1L) Treatment) for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC): CheckMate 9LA	David Carbone
15:30	15:38	Nivolumab (NIVO) + Ipilimumab (IPI) vs. Platinum-doublet Chemotherapy (Chemo) as First-line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1	Julie Brahmer
15:38	15:46	Tislelizumab Plus Chemotherapy vs. Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer	Jie Wang
15:46	15:56	Discussant	Deborah Doroshov
15:56	16:11	Live Q&A	Everett Vokes
16:11	16:19	Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study	Timothy Yap
16:19	16:27	Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression	Renata Ferrarotto
16:27	16:37	Discussant	Melina Marmarelis
16:37	16:55	Live Q&A	Everett Vokes
16:56	17:00	Tobacco Moment: Lung Cancer Screening and Smoking Cessation Clinical Trials (SCALE) Collaboration (NIH Study)	Stephanie Land
17:00	18:00	Virtual Posters & Virtual Exhibit Hall	

October 17, 2020

OLIGOMETASTATIC LUNG CANCER

Session Chairs: Jyoti Patel & Daniel Gomez

Start	End	Event	Presenter
7:00	7:04	Chairs Welcome	Jessica Donington Everett Vokes
7:04	7:06	Patient Perspective: Oligometastatic Lung Cancer	Frank Sierawski
7:06	7:16	Rationale for Aggressive Local Therapy in Metastatic Disease - Who to Refer and When?	Sawsan Rashdan

OLIGOMETASTATIC LUNG CANCER

Session Chairs: Jyoti Patel & Daniel Gomez

Start	End	Event	Presenter
7:16	7:26	Surgery for Local Consolidated Therapy for Patients with Oligometastatic Disease	Erin Gillaspie
7:26	7:36	Radiation for Local Consolidation Therapy	Tim Kruser
7:36	7:50	Live Q&A	Jyoti Patel Daniel Gomez

ORAL ABSTRACT SESSION 2

Session Chair: Phil Bonomi

Start	End	Event	Presenter
7:50	7:52	Patient Perspective	Melissa Crouse
7:52	8:00	Analysis of Resistance Mechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study	Justin Gainor
8:00	8:08	Tepotinib in Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping: Overall Efficacy Results from VISION Cohort A	Julien Mazieres
8:08	8:16	Real-World Progression-Free Survival in Oncogenic Driver-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Single-Agent Immunotherapy	Joseph Bodor
8:16	8:26	Discussant	Joel Neal
8:26	8:41	Live Q&A	Phil Bonomi
8:41	8:49	Lung Cancer Screening Modifies Smoking Behavior	Monica Reyes
8:49	8:57	Trends of Incidence and Burden of Metastatic Disease at Diagnosis of Lung Cancer after Implementation of Low Dose CT Screening in the United States	Manoj P. Rai
8:57	9:05	Volume Doubling Time and Radiomic Features Predict Tumor Behavior of Screen-Detected Lung Cancers in the National Lung Screening Trial (NLST)	Jaileene Perez-Morales
9:05	9:15	Discussant	Betty Tong
9:15	9:31	Live Q&A	Phil Bonomi
9:31	9:35	Tobacco Moment: Practicalities of Delivering Smoking Cessation Services in the Era of Telehealth	Bill Evans
9:35	9:50	BREAK	

TARGETED THERAPY

Session Chair: Taofeek Owonikoko

Start	End	Event	Presenter
9:50	9:52	Patient Perspective: Targeted Therapies	Frances Beard
9:52	9:56	Tobacco Product Update and Myth Busters	Mike Cummings
9:56	10:06	The Newest FDA Approvals for Targeted Therapies	Charu Aggarwal
10:06	10:16	Panel Discussion: Patient-Driven Research	Janet Freeman-Daily Ivy Elkins
10:16	10:26	Should Targeted Therapy Be 1st Line (Over Chemo, IO, or Chemo Plus IO) in All Patients, Regardless of the Targetable Mutations (e.g. ROS-1, RET, MET)?	Zosia Piotrowska
10:26	10:36	Beyond Tissue	Lynette Sholl
10:36	10:45	Live Q&A	Taofeek Owonikoko

CONCURRENT TUMOR BOARD 1: Stage III NACLC (EGFR+): A Complicated Case Complicated by COVID

Click here for more details regarding the case that will be discussed.

[NACLC2020.IASLC.org/wp-content/uploads/2020/10/NACLC2020-Stage-III-Tumor-Board-Case-moderator.pdf](https://naclc2020.iaslc.org/wp-content/uploads/2020/10/NACLC2020-Stage-III-Tumor-Board-Case-moderator.pdf)

Start	End	Event	Presenter
10:45	10:57	Case Presentation	Christine Bestvina
10:57	11:50	Panel Discussion	Ken Rosenzweig Rafael Santana-Davila Greg Durm Jessica Donington

CONCURRENT TUMOR BOARD 2: What's Next After Turrisi in Small Cell Lung Cancer. Clinical Challenges and Future Directions (SCLC)

Click here for more details regarding the case that will be discussed.

naclc2020.iaslc.org/wp-content/uploads/2020/10/SCLC-Tumor-Board-Case-PDF.pdf

Start	End	Event	Presenter
10:45	10:47	Patient Perspective	AJ Patel
10:47	10:57	Case Presentations	Neal McCall
10:57	11:50	Panel Discussion	Kristin Higgins Christine Hann Taofeek Owonikoko Brian Kavanagh

KEYNOTE ADDRESS & CLOSING REMARKS

Session Chair: Everett Vokes

Start	End	Event	Presenter
11:50	12:01	Paradigm Shift in Early Stage Disease	Mary Jo Fidler
12:01	12:11	What Does It Mean for Patients?	Jill Feldman
12:11	12:21	What Does It Mean for Surgeons?	Matthew Steliga
12:21	12:25	Tobacco Moment: Effective Integration of Smoking Cessation Services Across the Lung Cancer Continuum	Joelle Fathi
12:25	12:35	Live Q&A	Everett Vokes
12:35	12:45	Closing Remarks	Julie Brahmer Jessica Donington Everett Vokes Heather Wakelee